Bundibugyo

• An Ebola outbreak in the Democratic Republic of the Congo has surged to 3,200 confirmed cases and 1,405 deaths, marking the fastest growth rate ever recorded for any Ebola outbreak. • The crisis is exacerbated by a strike of healthcare workers who have walked off the job due to unpaid wages, severely hindering the medical response. • In a critical development, Oxford University has launched trials for the ChAdOx1 viral vector vaccine, the first shot specifically designed to target the Bundibugyo strain.

• A public health emergency occurred in May 2026 involving the Bundibugyo virus (Orthoebolavirus bundibugyoense) across the Democratic Republic of the Congo and Uganda. • The disease is characterized by high mortality rates, yet it currently lacks licensed vaccines, approved therapeutics, and widespread diagnostic implementation. • This outbreak highlights a critical gap in medical countermeasures and a lack of understanding regarding the virus's reservoir ecology.

• Scientists have launched the EBO-PEP clinical trial to test an experimental antiviral pill designed to prevent the Bundibugyo strain of Ebola after exposure. • The study is being led by the DRC's National Institute for Biomedical Research (INRB), France's ANRS Emerging Infectious Diseases, and the medical organization ALIMA. • This research is critical because there are currently no licensed vaccines or treatments specifically for the Bundibugyo strain, leaving a gap in outbreak control.

• A public health emergency occurred in May 2026 across the Democratic Republic of the Congo and Uganda due to an outbreak of Bundibugyo virus disease. • The disease, caused by *Orthoebolavirus bundibugyoense*, is characterized by high mortality rates and a lack of understood reservoir ecology. • Current medical responses are hindered by limited diagnostic implementation and a total absence of licensed vaccines or therapeutics specifically approved for this species.

• The Oxford Vaccine Group has launched the world's first Phase I clinical trial for a vaccine targeting the Bundibugyo ebolavirus. • The initiative is being supported by India's Serum Institute to develop a viable immunization strategy against this specific strain. • This trial is critical for expanding global preparedness against Ebola outbreaks and developing targeted vaccines for diverse virus variants.

• An international clinical trial has launched to evaluate potential treatments for Bundibugyo virus disease (BVD) as patient enrollment begins. • Sponsored by the WHO and coordinated by partners in the DRC, Belgium, and the UK, the study responds to an outbreak in the DRC where over 1,400 people have been diagnosed. • The trial is critical because there are currently no approved therapies for BVD, a disease that has already caused an estimated 440 deaths in the current outbreak.

• The World Health Organization (WHO) has added the first molecular diagnostic test for the Bundibugyo strain of Ebola virus to its Emergency Use Listing (EUL). • This risk-based procedure allows countries and procurement agencies to rapidly access quality-assured diagnostics before full regulatory approvals are finalized. • The move is critical as the Bundibugyo Ebola outbreak persists in the eastern Democratic Republic of the Congo, where insecurity and border movements have hindered containment.